Indian Pharma Urges Clear Distinction Between Spurious and Sub-Standard Drugs

The Indian Pharmaceutical Alliance (IPA) emphasizes the need to distinguish between spurious and sub-standard drugs. A recent report by CDSCO flagged 50 products as 'not of standard quality,' drawing criticism from major drug firms. IPA calls for stringent measures to protect India's pharmaceutical reputation.

The Indian Pharmaceutical Alliance (IPA) has stressed the importance of differentiating between spurious and sub-standard drugs, cautioning that linking counterfeit products with legitimate manufacturers can cause severe reputational and financial damage.

This call to action follows a recent CDSCO report identifying over 50 products as 'not of standard quality'. Leading pharmaceutical companies such as Sun Pharma and Glenmark refuted these claims, asserting their adherence to quality standards and labeling the flagged medicines as counterfeits.

IPA Secretary General Sudarshan Jain emphasized that manufacturing spurious drugs is a grave criminal offense with significant public health risks. He urged for a clear differentiation between NSQ and spurious drugs, highlighting the importance of India's global standing and the need to ensure the pharmaceutical industry's credibility.

(With inputs from agencies.)